Posted On: 11/07/2014 10:35:31 AM
Post# of 30066
BC-sera Pro has been taken off the AMBS web page-
BC-SeraPro (The Breast Cancer Diagnostic Blood Test) may be the wildcard and may be potentially "immediately ready" for fast-track commercialization much sooner than LymPro will be. BC-SeraPro could come into play as a unexpected pleasant surprise to everyone!
Amarantus now owns the IP rights to BC-SeraPro after acquiring all the IP rights from Power3 Medical Products:
http://ir.stockpr.com/amarantus/company-news/...l-products
An old press release article by Power3 Medical Products concerning the commercialization of BC-SeraPro:
http://www.reuters.com/article/2008/01/08/idU...BW20080108
From the recent Amarantus 10-K:
For the next 12 months, the Company intends to focus on the development of MANF and the development of LymPro. The Company intends to use minimal resources and look for appropriate research partnership opportunity to further develop its BC-SeraPro, NuroPro and PhenoGuard assets.
(0)
(0)
